Breakthroughs in Imaging Modalities for Prostate Cancer

Five expert panelists in prostate cancer consider how recent advances in imaging, particularly PSMA-PET, have impacted the field, and highlight guidelines that may aid clinicians in selecting amongst the available imaging modalities.

Related Videos
Experts on CRC
David Gerber, MD
Evan Y. Yu, MD, professor, medical oncology, assistant fellowship director, University of Washington School of Medicine, professor, Clinical Research Division, clinical research director, Genitourinary Medical Oncology, Fred Hutchinson Cancer Center, medical director, clinical research support, Fred Hutchinson Cancer Research Consortium
Michael A. Carducci, MD, professor of oncology, AEGON Professor of Prostate Cancer Research, Johns Hopkins Medicine
Expert on breast cancer
Michael S. Cookson, MD, MMHC, professor, chairman of urology, University of Oklahoma College of Medicine, chief, Urology, Stephenson Cancer Center
Experts on BTC
Related Content

ASCT Following First Complete Remission Does Not Improve Real-World Survival in Mantle Cell Lymphoma

March 19th 2023

Rosenthal Discusses the Need for Standardized Care in AYA Hodgkin Lymphoma

February 2nd 2023

FDA Expands Indication of Illuccix Companion Diagnostic for PSMA-Directed Radioligand Therapy in Metastatic Prostate Cancer

March 16th 2023

Goetz and Choong Describe the Need for Adjuvant Endocrine Therapy in ER-positive Breast Cancer

January 23rd 2023

China ARCHES Study Meets Primary, Secondary End Points in Metastatic Prostate Cancer

March 14th 2023

Utilizing PARP Inhibitors in Metastatic Castration-Resistant Prostate Cancer in a Tailored Fashion

March 14th 2023

ASCT Following First Complete Remission Does Not Improve Real-World Survival in Mantle Cell Lymphoma

March 19th 2023

Rosenthal Discusses the Need for Standardized Care in AYA Hodgkin Lymphoma

February 2nd 2023

FDA Expands Indication of Illuccix Companion Diagnostic for PSMA-Directed Radioligand Therapy in Metastatic Prostate Cancer

March 16th 2023

Goetz and Choong Describe the Need for Adjuvant Endocrine Therapy in ER-positive Breast Cancer

January 23rd 2023

China ARCHES Study Meets Primary, Secondary End Points in Metastatic Prostate Cancer

March 14th 2023

Utilizing PARP Inhibitors in Metastatic Castration-Resistant Prostate Cancer in a Tailored Fashion

March 14th 2023

ASCT Following First Complete Remission Does Not Improve Real-World Survival in Mantle Cell Lymphoma

March 19th 2023

Rosenthal Discusses the Need for Standardized Care in AYA Hodgkin Lymphoma

February 2nd 2023

FDA Expands Indication of Illuccix Companion Diagnostic for PSMA-Directed Radioligand Therapy in Metastatic Prostate Cancer

March 16th 2023

Goetz and Choong Describe the Need for Adjuvant Endocrine Therapy in ER-positive Breast Cancer

January 23rd 2023

China ARCHES Study Meets Primary, Secondary End Points in Metastatic Prostate Cancer

March 14th 2023

Utilizing PARP Inhibitors in Metastatic Castration-Resistant Prostate Cancer in a Tailored Fashion

March 14th 2023